Gapping up
In reaction to strong earnings/guidance:
- BCOV +11.2%, FBHS +10.3%, GNC +9.8%, FB +9%, SAM +8.9%, AXTI +7.8%, MSFT +4.9%, WAB +4.5%, LRCX +4.4%, NCI +4.4%, CHDN +4.2%, HSY +4.2%, KN +4%, NOW +4%, GFI +3.6%, IP +3.5%, MDCO +3.4%, CVI +3.2%, AZPN +3%, CLF +2.9%, BWA +2.3%, WPG +2%, PYPL +2%, YNDX +2%, LUV +2%, TAK +2%, ABBV +2%, LKQ +1.8%, LLEX +1.8%, SHOO +1.8%, IRM +1.7%, WCN +1.6%, DRE +1.4%, PDS +1.4%, BMY +1.3%, BBD +1.2%, VLO +1.2%, MEOH +1.1%, UAN +1.1%, TAL +1.1%, ROP +1%, CLB +0.8%, UFPI +0.8%, WM +0.8%, SUI +0.7%, NEM +0.7%, CMG +0.6%
Other news:
- QTNT +13.8% (Quotient reports "positive" initial EU field trial performance data for MosaiQ Serological Disease Screening Microarray)
- MAXR +6.1% (to collaborate with NTT DATA and Toyota Research Institute to build high-definition maps for autonomous vehicles from space)
- ACRS +5.3% (submits IND to FDA for ATI-450)
- AMAT +2.8% (following LRCX results)
- ZUO +2.7% (following CEO appearance on CNBC's Mad Money)
- ZM +2% (rebounding from Wednesday's 8% decline; Cboe Global Markets plans listing of options on April 25)
- SFLY +1.2% (following afternoon move higher on reports of PE interest)
- TELL +1% (discloses entry into master liquefied natural gas sale and purchase agreement and related confirmation notices with an unrelated third-party LNG merchant)
Analyst comments:
- NVS +1.8% (upgraded to Buy from Neutral at Guggenheim)
- WYNN +1.8% (upgraded to Buy from Neutral at BofA/Merrill)
- LAD +1.5% (upgraded to Overweight from Equal-Weight at Stephens)
- AXP +1.2% (upgraded to Overweight from Equal-Weight at Morgan Stanley)